Vertex Pharmaceuticals Incorporated ($VRTX) Stock Forecast: Up 0.5% Today

What is Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals (VRTX) is a biotechnology company based in Boston, Massachusetts, known for its focus on developing therapies for serious diseases.

Why is Vertex Pharmaceuticals Incorporated going up?

VRTX stock is up 0.5% on Nov 4, 2025 15:36

• VRTX had a strong bullish movement today.
• The company is expected to report higher Q3 earnings, with analysts revising their forecasts ahead of the earnings call.
• Over the past 15 years, Vertex Pharmaceuticals has significantly outperformed the market, showcasing an average annual return of 18.0%.
• Despite a slight -1.23% dip in stock price recently, the overall market sentiment remains positive for Vertex Pharmaceuticals.

VRTX Price Chart

VRTX Technical Analysis

VRTX News

Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Vertex Pharmaceuticals ( NASDAQ:VRTX )

Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) will release earnings results for the first quarter, after the closing bell on Monday, Nov. 3. Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.58 per share, up from $4.38 per share in the year-ago ...

https://www.benzinga.com/analyst-stock-ratings/price-target/25/11/48602050/vertex-pharmaceuticals-likely-to-report-higher-q3-earnings-these-most-accurate

Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today - Vertex Pharmaceuticals ( NASDAQ:VRTX )

Vertex Pharmaceuticals ( NASDAQ:VRTX ) has outperformed the market over the past 15 years by 5.91% on an annualized basis producing an average annual return of 18.0%. Currently, Vertex Pharmaceuticals has a market capitalization of $107.16 billion.

https://www.benzinga.com/insights/news/25/10/48547844/heres-how-much-100-invested-in-vertex-pharmaceuticals-15-years-ago-would-be-worth-today

Vertex Pharmaceuticals ( VRTX ) Stock Moves -1.23%: What You Should Know

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $417.21, denoting a -1.23% move from the preceding trading day.

https://www.zacks.com/stock/news/2780765/vertex-pharmaceuticals-vrtx-stock-moves--123-what-you-should-know

Trending Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Down 5.4% Today

Evergy Inc. ($EVRG) Stock Forecast: Down 1.9% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.5% Today

Novo Nordisk A/S ($NVO) Stock Forecast: Down 5.2% Today

Chegg Inc. ($CHGG) Stock Forecast: Up 12.1% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 21.9% Today

CarMax Inc ($KMX) Stock Forecast: Down 25.1% Today

Reddit Inc ($RDDT) Stock Forecast: Down 6.1% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Down 5.1% Today

XRP ($XRP) Crypto Forecast: Down 5.1% Today

Vertex Pharmaceuticals Incorporated Price History

11.03.2025 - VRTX Stock was up 5.0%

• Vertex Pharmaceuticals (VRTX) stock had a strong bullish movement today, possibly driven by the news of securing approval for the expanded use of its CF drug Kaftrio in Europe.
• The expanded use of Kaftrio to treat a larger population in the EU with rare mutations of cystic fibrosis could have positively impacted investor sentiment and contributed to the stock's upward momentum.
• The positive news of regulatory approval for Vertex's drug in a new market could have instilled confidence in investors regarding the company's growth potential and future revenue streams, leading to the bullish movement in the stock price today.

03.10.2025 - VRTX Stock was down 2.4%

• Despite outperforming the market over the past 15 years with an average annual return of 18.0%, Vertex Pharmaceuticals (VRTX) experienced a -1.23% decrease in stock price today.
• The decrease in stock price could be attributed to profit-taking by investors after a period of strong performance.
• Investors might be reacting to recent market conditions or specific news related to Vertex Pharmaceuticals, prompting the bearish movement.
• It's essential to monitor further developments to understand if this bearish trend is a short-term correction or a more prolonged shift in market sentiment towards Vertex Pharmaceuticals.

16.08.2025 - VRTX Stock was down 1.8%

• VRTX stock faced a notable decline, closing at $388.55, reflecting a -2% drop from the prior day.
• Although Vertex Pharmaceuticals has a historically strong performance, the recent decline in the market might be linked to profit-taking among investors.
• The broader market surge could have prompted some traders to redistribute their investments, resulting in a brief downturn in VRTX stock.
• Investors are advised to stay vigilant about forthcoming healthcare sector updates that could influence Vertex Pharmaceuticals' stock behavior.

04.10.2025 - VRTX Stock was up 0.5%

• VRTX had a strong bullish movement today.
• The company is expected to report higher Q3 earnings, with analysts revising their forecasts ahead of the earnings call.
• Over the past 15 years, Vertex Pharmaceuticals has significantly outperformed the market, showcasing an average annual return of 18.0%.
• Despite a slight -1.23% dip in stock price recently, the overall market sentiment remains positive for Vertex Pharmaceuticals.

05.07.2025 - VRTX Stock was down 18.4%

• Vertex Pharmaceuticals (VRTX) experienced a strong bearish movement today.
• The bearish trend could be attributed to analysts cutting their forecasts for the company after the Q2 results, despite reporting better-than-expected earnings. This adjustment may have led to a loss of investor confidence.
• Additionally, the disappointing results of the VX-993 trial might have contributed to the negative sentiment surrounding the stock, as investors may have been expecting more positive outcomes.
• Overall, the combination of lowered forecasts and unsatisfactory trial results likely led to the bearish movement in Vertex Pharmaceuticals' stock today.

31.00.2025 - VRTX Stock was up 6.9%

• VRTX stock experienced a strong bullish movement.
• Vertex Pharmaceuticals secured FDA approval for a non-opioid pain treatment and reached a reimbursement agreement with NHS England for its gene therapy, driving positive sentiment.
• The market reacted positively to these advancements in pain management and expanded access to treatments for sickle cell disease, propelling VRTX stock higher.

05.07.2025 - VRTX Stock was down 13.7%

• There was a notable downward movement in the stock today.
• Recent reports on Q2 earnings and VX-993 trial outcomes fell short of projections, contributing to a decrease in the stock's value.
• Despite a generally positive market environment, with Dow futures seeing a slight increase of about 0.1%, Vertex Pharmaceuticals experienced a substantial decline following disappointing trial results.
• Analysts have been closely monitoring the company's stock performance, noting its history of outperforming the market but encountering challenges in the current quarter.

30.08.2025 - VRTX Stock was down 1.2%

• The bearish movement in VRTX could be due to profit-taking by investors after a period of significant gains.
• The bullish analyst upgrades for other companies may have diverted attention and capital away from VRTX, leading to a decline in its stock price.
• Investors might be rotating out of biotech stocks like VRTX and into other sectors, following the shifting recommendations from top Wall Street analysts.
• Overall, the bearish movement in VRTX today could be a combination of sector rotation, profit-taking, and the influence of bullish sentiment on other stocks in the market.

14.04.2025 - VRTX Stock was down 5.3%

• Despite Vertex Pharmaceuticals' strong performance over the past 15 years, the stock faced a bearish movement today.
• Speculation that Vertex Pharmaceuticals will bounce suggests that there may be underlying factors contributing to the temporary decline.
• The market may be reacting to short-term fluctuations or profit-taking by investors, leading to the bearish movement in VRTX today.
• Investors should monitor the situation closely to determine if this is a temporary dip or the beginning of a more sustained trend.

08.06.2025 - VRTX Stock was up 2.3%

• Vertex Pharmaceuticals (VRTX) saw a strong bullish movement, closing at $452.16 with a +1.56% change.
• The bullish movement in VRTX could be attributed to positive developments in its pipeline or potential regulatory approvals.
• Despite the overall market dip, investors showed confidence in Vertex Pharmaceuticals, possibly due to promising clinical trial results or optimistic revenue forecasts.
• The resilience of VRTX in a slightly bearish market indicates strong investor sentiment and belief in the company's growth prospects.

06.04.2025 - VRTX Stock was down 10.9%

• Experienced a strong bearish movement today.
• Fell after missing analyst estimates on both earnings and revenue for the first quarter.
• Despite raising the low end of its full-year 2025 revenue guidance, the market reacted negatively to the missed expectations.
• Analyst downgrades and concerns about the company's recent performance may have contributed to the bearish trend in the stock price.

11.02.2025 - VRTX Stock was down 2.7%

• The bearish movement in VRTX stock today might be due to the pricing placement of their newly approved pain treatment, Journavx, on UnitedHealth's Optum Rx formularies.
• Concerns may arise over the $15.50 cost per 50 mg tablet of Journavx, which surpasses that of opioids, potentially affecting its market acceptance and profitability.
• Despite Vertex's robust Q4 sales figures, market response to Journavx's pricing strategy could have overshadowed positive financial outcomes, contributing to the downtrend in the stock price today.